Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 11Obesity 4Sarcopenia 3Polycystic Ovary Syndrome 3Neoplasms 3Melanoma 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Malnutrition 2Lymphoma, Follicular 2Colorectal Neoplasms 2Breast Carcinoma In Situ 2Wound Infection 1Weight Loss 1Urinary Bladder Neoplasms 1Surgical Wound Infection 1Stomach Neoplasms 1Smoldering Multiple Myeloma 1Skin Neoplasms 1Psoriasis 1Precancerous Conditions 1Postoperative Complications 1Polyps 1Phagocyte Bactericidal Dysfunction 1Pain 1Paget's Disease, Mammary 1Overweight 1Osteoarthritis 1Olfaction Disorders 1Non-alcoholic Fatty Liver Disease 1

Interventions

Exercise 6Transcranial Direct Current Stimulation 4Walking 3Memantine 3Tablets 2Standard of Care 2Methods 2Donepezil 2Cognitive Behavioral Therapy 2mazdutide 1lithium sulfate 1lime 1fasudil 1enzalutamide 1blueberry extract 1beta Carotene 1acetaminophen, aspirin, caffeine drug combination 1XENP 1595 1Vitamin E 1Vitamin D 1Ultraviolet Therapy 1Transcranial Magnetic Stimulation 1Time 1Therapeutics 1Tai Ji 1Sugars 1Sodium Chloride 1Sirolimus 1Silymarin 1Riluzole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cognitive Dysfunction × Docosahexaenoic Acids × Clear all
NCT02517502 2022-01-24

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

University of Kansas Medical Center

Phase EARLY_PHASE1 Completed
24 enrolled
Breast

Breast Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡